PAK6 promotes homologous-recombination to enhance chemoresistance to oxaliplatin through ATR/CHK1 signaling in gastric cancer

Chemoresistance remains the primary challenge of clinical treatment of gastric cancer (GC), making the biomarkers of chemoresistance crucial for treatment decision. Our previous study has reported that p21-actived kinase 6 (PAK6) is a prognostic factor for selecting which patients with GC are resist...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Weicai, Han, Zhen, Sun, Zepang, Feng, Hao, Zhao, Liying, Yuan, Qingyu, Chen, Chuanli, Yu, Shitong, Hu, Yanfeng, Yu, Jiang, Liu, Hao, Li, Guoxin, Jiang, Yuming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334622/
https://www.ncbi.nlm.nih.gov/pubmed/35902562
http://dx.doi.org/10.1038/s41419-022-05118-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334622/
https://www.ncbi.nlm.nih.gov/pubmed/35902562
http://dx.doi.org/10.1038/s41419-022-05118-8

Ejemplares similares